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Abstract 
Routinely collected data about health in medical records, 
registries and hospital activity statistics is now routinely collected in an 
electronic form. The extent to which such sources of data are now 
being routinely accessed to deliver efficient clinical trials, is unclear. 
The aim of this study was to ascertain current practice amongst a 
United Kingdom (UK) cohort of recently funded and ongoing 
randomised controlled trials (RCTs) in relation to sources and use of 
routinely collected outcome data. 
Recently funded and ongoing RCTs were identified for inclusion by 
searching the National Institute for Health Research journals library. 
Trials that have a protocol available were assessed for inclusion and 
those that use or plan to use routinely collected health data for at 
least one outcome were included. Routinely collected data sources 
and outcome information were extracted. 
A total of 279 studies were identified with 102 eligible for data 
extraction. An Electronic Health Record (EHR) was the sole source of 
outcome data for at least one outcome in 46 trials. The most frequent 
sources are Hospital Episode Statistics (HES) and Office for National 
Statistics (ONS), with the most common outcome data to be extracted 
being on mortality, hospital admission, and health service resource 
use. 
Our study has found that around half of publicly funded trials in a UK 
cohort plan to collect outcome data from routinely collected data 
sources. This is much higher than the figure of 8% found in a cohort of 
189 RCTs published since 2000, the majority of were carried out in 
North America (McCord et al., 2019).
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Introduction
Routinely collected data about health in medical records, reg-
istries and hospital activity statistics is now routinely collected 
in an electronic form. Progress in achieving connectivity, data 
linkage and security now offers the possibility of better use of 
this data for research purposes. For example, recent evidence 
shows the utility of long-term follow-up of trial patients through 
the electronic health record (EHR) (Fitzpatrick et al., 2018). Inno-
vative data-enabled study designs can answer pressing knowledge 
gaps in research evidence. However, the extent to which such 
sources of data are now being routinely employed in research 
to deliver efficient clinical trials, potentially at a wide scale, 
is unclear.
The aim of this study was to ascertain current practice amongst 
a United Kingdom (UK) cohort of recently funded and ongo-
ing randomised controlled trials (RCTs) in relation to sources 
and use of routinely collected outcome data. We define rou-
tinely collected health data to be data collected without specific 
a priori research questions developed prior to using the data for 
research.
Methods
Inclusion criteria
The following inclusion criteria were used: 
1.     Ongoing RCT of any type including feasibility or pilot 
work, funded by the National Institute for Health 
Research (NIHR) Health Technology Assessment (HTA) 
programme;
2.     use of routinely collected health data for at least one study 
outcome; and
3.     availability of a protocol.
Search methods
A search of the NIHR Journals Library was undertaken to find 
protocols registered as of 25/10/2019. The search fields and 
terms used to select were: 
1.     Search term: ‘Random’
2.     Research type: ‘Primary research’
3.     Programme: ‘HTA’
4.     Status: ‘Research in progress’
If the final published report was shown alongside the protocol 
this was taken to mean that the RCT was not ongoing but the 
status had not been updated to ‘Published’, and the study was 
excluded.
In the absence of a protocol, the study was excluded. For stud-
ies with multiple protocol versions, the most recently available 
version was used.
Data extraction
One person (AM) extracted the information and categorised 
each EHR, with a second person (PW) checking classifications 
and explanations. The information extracted was as follows: 
Lead Investigator surname, year started, ISRCTN, project 
title, study type, use of routinely collected health data for at 
least one study outcome, availability of a protocol, any details 
of EHR data quality assessment prior to use, EHR name, 
reasons for sourcing outcome data from EHR, specific outcomes 
and outcome type where clear data to be used will come from 
named EHRs.
Results
Figure 1 shows the study flow diagram. There were 102 
eligible trials available for further study.
Table 1 shows the reasons for collecting trial outcome data 
from routine sources. The EHR was the sole source of outcome 
data for at least one outcome in 46 trials (categories 3, 4 and 6 
in Table 1). In five of these 46 protocols there was reference 
to prior feasibility work confirming aspects of the quality of 
the data to be sufficient for the main trial. Of the 102 trials, 14 
(categories 7a-7d in Table 1) planned to assess the feasibility of 
using the EHR data sources during the trial, although details 
of the assessment were often lacking. Raw data for Figure 1 
and Table 1 and Table 2 are available (see Underlying data, 
McKay et al. (2020)).
Table 2 shows the sources of outcome data to be used in these 
46 studies. The most frequent sources are Hospital Episode 
Statistics (HES) and Office for National Statistics (ONS), 
with the most common outcome data to be extracted being on 
mortality, hospital admission, and health service resource use 
(see Underlying data, Data Set 5; McKay et al. (2020)). The full 
list of data sources is given in Extended data, Supplementary 
Table 1 (McKay et al., 2020).
Discussion
Our study has found that around half of publicly funded tri-
als in a UK cohort plan to collect outcome data from routinely 
collected data sources. This is much higher than the figure of 
8% found in a cohort of 189 RCTs published since 2000, the 
majority of which were carried out in North America (McCord 
et al., 2019).
Very few trial teams described any assessments of data qual-
ity from EHRs in the protocol. Work is ongoing that should 
determine whether such information should be reported in the 
trial publication (Kwakkenbos et al., 2018). An extension to the 
SPIRIT guidelines for EHR-supported trials is soon to be ini-
tiated, and will determine whether this information should be 
included in the trial protocol. As a minimum, it is recommended 
that trialists provide evidence in any funding application about 
the quality of the data from the EHR.
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Figure 1. PRISMA flow diagram.
Table 1. Reasons for sourcing outcome data from EHRs in 102 studies. Multiple categories can apply to a single study.
Categories Total
(1) (1a) ‘Supplementing data collection for withdrawn patients (consent asked for at time of withdrawal)’ 7
(1b) ‘Supplementing data collection for lost-to-follow-up patients’ 8
(1c) ‘Supplementing data collection for withdrawn patients (consent NOT ASKED FOR at time of withdrawal)’ 2
(1e) ‘Continued data collection for withdrawn patients (consent asked for at time of withdrawal)’ 1
(2) (2) ‘Supplementing data collection for unobtainable/missing data’ 3
(3) (3a) ‘As the sole source of all outcome data’ 0
(3b) ‘As the sole source of all outcome data except for data related to protocol adherence and adverse event 
reporting being collected using CRFs’ 0
(4) (4) ‘As the sole source of some outcome data’ 43
(5) (5a) ‘As a source of some outcome data, alongside other sources for the same outcome data (e.g. CRF)’ 51
(5b) ‘As a source of some outcome data, but collected by CRF if unable to access data’ 3
(6) (6a) ‘Registry trial: As the sole source of outcome data with purpose-built Module to collect remaining outcome data’ 1
(6b) ‘Registry trial: All outcome data collected through multiple EHRs except for questionnaire data’ 1
(6c) ‘Registry trial: All outcome data collected through multiple EHRs except for some baseline data, 
questionnaire data and other patient-reported data’ 1
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Table 2. Categories of EHR sources of outcome data in 
46 studies where this was the sole source for at least one 
outcome.
Source Number (%)
(i) Primary care data (all regional equivalents) 8 (17%)
(ii) HES (and/or regional equivalents) 27 (59%)
(iii) ONS (and/or regional equivalents) 27 (59%)
(iv) Data collected specifically for patient group 
or healthcare intervention (to include patient 
registries, ICNARC, ambulance, etc)
26 (57%)
(v) Other 5 (11%)
Categories Total
(7) (7a) ‘EHR data compared to trial collected data as part of feasibility assessment criteria’ 11
(7b) ‘EHR data compared to trial collected data as a main trial secondary outcome’ 1
(7c) ‘EHR data compared to trial collected data and then collect long-term follow-up data as part of trial’ 1
(7d) ‘EHR data compared to trial collected data and then collect long-term follow-up data after trial has been 
completed’ 1
(7e) ‘Representativeness of randomised patients compared with all eligible patients using EHR data as part 
of feasibility assessment criteria’ 1
(8) (8a) ‘Participants flagged with NHS Digital/other: Check health status of patient prior to contacting in case patient has died’ 2
(8b) ‘Participants flagged with NHS Digital/other: Check health status/notification of any deaths, causes’ 12
(9) (9) ‘Set up mechanisms for long-term follow-up’ 4
(10) (10) ‘Patients asked to provide written consent for continuation in the study once have regained capacity. Those who prefer not to be actively involved in the study follow-up, then asked to provide co 1
Total 155
Data availability
Underlying data
Figshare: Use of routinely collected data in a UK cohort of 
publicly funded randomised clinical trials. https://doi.org/10.6084/
m9.figshare.12185193 (McKay et al., 2020).
This project contains the following underlying data: 
•       Data_Set_1_Details_and_Figure_1_v1.0.csv. (Study iden-
tifiers and raw data used for Figure 1.)
•      Data_Set_2_Table_1_v1.0.csv. (Raw data used for 
Table 1.)
•      Data_set_3_Supp_Table_1_v1.0.csv. (Raw data used for 
Supplementary Table 1.)
•      Data_set_4_Table_2_v1.0.csv. (Raw data used for 
Table 2.)
•      Data_set_5_Outcomes_using_EHR_data_v1.0.csv. 
(Raw data showing details of outcomes using EHR 
data.)
Extended data
Figshare: Use of routinely collected data in a UK cohort of 
publicly funded randomised clinical trials. https://doi.org/10.6084/
m9.figshare.12185193 (McKay et al., 2020).
This project contains the following extended data: 
•       Supplementary Table 1 - EHR sources of outcome data 
v1.0.pdf. (Supplementary Table 1.)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Sharon Love   
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This is a review of the protocols of RCTs, currently in progress, funded by NIHR, UK. RCTs were 
selected from NIHR HTA funding stream list if they claimed to be using routinely collected data for 
at least one study outcome. The authors found 102 trial protocols matching this criteria and from 
data extraction that 46 of these were using routinely collected data solely for at least one 
outcome. The research also found that a handful referenced previous feasibility work confirming 
the quality of the EHR and also gives a useful table categorising for the 102 trials how they used 
EHR. 
 
Major Comments 
I have only one major comment and it is the reason for both the ‘partly’ options below. The sample 
was selected to be using routinely collected data for at least one study outcome. Therefore I think 
the main result should contain this information. I consider that “in a UK cohort” is not enough of a 
description of the cohort. The fact that the sample was selected based on using routine data for an 
outcome is crucial in the interpretation. 
 
The main result is that of 102 protocols using routinely collected data for an outcome, 46 were 
using routinely collected data as their sole source for at least one outcome. 46/102=45%. Around a 
half of NIHR HTA funded trials that had an uploaded protocol and used routinely collected health 
data for at least one study outcome, used solely routinely collected data for at least one trial 
outcome. 
I think this is an important result. 
 
Minor comments
Abstract – last part of the last sentence has a word missing “The majority of which were 
carried out in North America”. 
 
1. 
If you have space in the text, it would be useful to add the information that 30 were omitted 
due to not having a protocol. 
 
2. 
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The flow chart shows you selected the papers by selecting RCT, those that had a protocol 
and then those using routinely collected data for at least one outcome. I would be tempted 
to list the inclusion criteria in the paper in the same order. 
 
3. 
The second inclusion criteria is “use of routinely collected health data”. Elsewhere you use 
the term EHR. I would be tempted to be consistent. 
 
4. 
Table 1: category 10 description appears incomplete. 
 
5. 
Table 1: could you add a footnote of the definition of a registry trial?6. 
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Are sufficient details of methods and analysis provided to allow replication by others?
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If applicable, is the statistical analysis and its interpretation appropriate?
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Are all the source data underlying the results available to ensure full reproducibility?
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Are the conclusions drawn adequately supported by the results?
Partly
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Major comments: Thanks for your important comments. We have made these clearer within 
the article update to version 2. 
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Major comments part 1: We have now made it clear that the “UK cohort” is “NIHR HTA trials 
with a protocol” ongoing at the stated data extraction date. 
  
Major comments part 2: We have now made this clearer. 
  
Minor comments: Thank you for your comments. We have addressed them all within the 
article update to version 2. In relation to one specific comment, we have chosen to use 
‘routinely collected health data (RCHD)’ throughout rather than ‘Electronic Health Record 
(EHR)’ for consistency.  
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